ARA-290 (16MG)

What Is ARA-290 and Why Buy It for Research?

Buy ARA-290 16mg in Switzerland for research into innate repair receptor signaling, tissue protection, and anti-inflammatory mechanisms. Specifically, ARA-290 (also known as Cibinetide, PHBSP, or Pyroglutamate Helix B Surface Peptide) is a synthetic 11-amino acid linear peptide derived from the helix-B domain of erythropoietin (EPO). Structurally, it features the sequence Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (Pyr-EQLERALNSS) with a pyroglutamate at the N-terminus, giving it a molecular weight of approximately 1,257 Da.

In scientific research, ARA-290 serves as a molecular tool for studying the tissue-protective and anti-inflammatory functions of erythropoietin independently of its hematopoietic (red blood cell-stimulating) activity. Researchers consider this peptide particularly valuable for investigating the innate repair receptor (IRR), a heterodimeric complex composed of the EPO receptor (EPOR) and the beta-common receptor (CD131). Furthermore, Core Peptides supplies ARA-290 as a lyophilized powder in a 16mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available through trusted suppliers.

ARA-290 Research Overview: Buy ARA-290 16mg in Switzerland for Innate Repair Receptor Studies

Centrally, research into ARA-290 has focused on its function as a selective agonist of the innate repair receptor (IRR). Endogenously, erythropoietin has two distinct receptor interactions: one through the classical homodimeric EPO receptor (EPOR/EPOR) that drives erythropoiesis, and another through a heterodimeric complex termed the innate repair receptor, composed of EPOR and CD131. ARA-290 selectively activates the IRR without engaging the classical EPOR homodimer, thereby delivering tissue-protective, anti-inflammatory, and regenerative effects without the cardiovascular risks associated with increased red blood cell production.

Michael Brines and Anthony Cerami at Araim Pharmaceuticals engineered ARA-290 from the helix-B surface domain of EPO after identifying the specific three-dimensional structure responsible for tissue-protective signaling. Accordingly, researchers can buy ARA-290 16mg in Switzerland from Core Peptides to support their investigations into innate repair receptor signaling, neuroprotection, and anti-inflammatory pathways.

How Does ARA-290 Work in Research?

Mechanistically, ARA-290’s proposed action involves functioning as a selective agonist of the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (also known as CSF2RB). This receptor complex belongs to the type I cytokine receptor family and expresses on a wide range of cell types, including neurons, endothelial cells, immune cells, and Schwann cells.

Activation of the IRR by ARA-290 triggers several downstream pathways. Specifically, it antagonizes the production and effects of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), and reduces macrophage activation. Additionally, ARA-290 activates JAK2-STAT signaling in injured tissue, promotes endothelial protection against ischemic injury, and supports peripheral nerve regeneration.

Furthermore, research has demonstrated that ARA-290 inhibits activation of the NLRP3 inflammasome in Schwann cells after sciatic nerve injury by reducing NF-κB phosphorylation and reactive oxygen species (ROS) production. This anti-inflammatory action, combined with its tissue-protective effects, makes ARA-290 a valuable tool for studying neuropathic pain, ischemic injury, and chronic inflammatory conditions. The peptide also exhibits a short plasma half-life of approximately 2 minutes intravenously and 20 minutes subcutaneously, yet its protective effects are equivalent to those of EPO or carbamylated EPO (CEPO).

Why Is ARA-290 Studied in Switzerland?

Primarily, researchers study ARA-290 because it represents a well-characterized EPO-derived peptide that enables investigation of tissue-protective signaling without the confounding effects of erythropoiesis. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying neuroprotection, inflammation resolution, and tissue repair.

Preclinical studies have demonstrated ARA-290’s efficacy across multiple research domains. For example, both EPO and ARA-290 inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models. Additionally, ARA-290 has shown promise in reducing vascular inflammation and promoting neuroprotection in Alzheimer’s disease models. In animal models of aging, cibinetide has demonstrated the capacity to decrease age-related decline in heart function and frailty. Furthermore, clinical research has investigated ARA-290 for sarcoidosis-associated small-fiber neuropathy and diabetic peripheral neuropathy, with studies reporting improved corneal nerve fiber density and reduced neuropathic pain. Ultimately, researchers can buy ARA-290 16mg in Switzerland to access a research tool that may help uncover mechanisms underlying tissue protection, neuroinflammation, and regenerative signaling.

ARA-290 Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
Innate Repair Receptor Signaling	IRR agonism, EPOR/CD131 heterodimer activation	Mechanistic / In Vitro
Neuroprotection	Peripheral nerve regeneration, neuropathic pain, Schwann cell signaling	Animal / Preclinical / Clinical
Anti-Inflammatory Research	NLRP3 inflammasome inhibition, NF-κB, TNF-α reduction	Mechanistic / In Vitro / In Vivo
Ischemic Injury	Endothelial protection, ischemia-reperfusion, retinal ischemia	Animal / Preclinical
Diabetic Complications	Peripheral neuropathy, metabolic control, corneal nerve density	Clinical
Sarcoidosis Research	Small-fiber neuropathy, neuropathic pain, corneal nerve regeneration	Clinical
Aging and Frailty	Cardiac function decline, age-related tissue protection	Animal / Preclinical

ARA-290 Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
ARA-290	Tissue protection, anti-inflammatory, neuroprotection	Selective IRR agonist (EPOR/CD131)	11-amino acid peptide; non-erythropoietic
Full-Length EPO	Erythropoiesis, tissue protection	EPOR homodimer and IRR activation	166 amino acids; stimulates red blood cell production
Carbamylated EPO (CEPO)	Tissue protection, anti-inflammatory	IRR activation (modified EPO)	Modified full-length EPO; no erythropoiesis
BPC-157	Tissue healing, angiogenesis	Growth factor modulation	Different mechanism; no EPO involvement

Comparatively, ARA-290 differs from full-length erythropoietin in its structure and receptor selectivity. On the one hand, full-length EPO consists of 166 amino acids and activates both the classical EPOR homodimer (driving erythropoiesis) and the IRR (driving tissue protection). On the other hand, ARA-290 is an 11-amino acid peptide that selectively activates only the IRR, making it a more focused tool for studying tissue-protective signaling without the confounding effects of red blood cell stimulation. In contrast, carbamylated EPO is a modified full-length protein that also lacks erythropoietic activity, while BPC-157 operates through entirely different mechanisms unrelated to EPO signaling.

Research Applications for ARA-290 in Switzerland

Scientists have investigated ARA-290 across several research domains:

• Innate Repair Receptor Research: Researchers use ARA-290 to study IRR activation, EPOR/CD131 heterodimer signaling, and downstream JAK2-STAT pathways.
• Neuroprotection and Nerve Regeneration: Investigations have explored ARA-290’s effects on peripheral nerve regeneration, Schwann cell signaling, and neuropathic pain models.
• Anti-Inflammatory Research: ARA-290 serves as a tool for studying NLRP3 inflammasome inhibition, NF-κB phosphorylation, and pro-inflammatory cytokine reduction.
• Ischemic Injury Studies: The compound is used to investigate endothelial protection, ischemia-reperfusion injury, and retinal ischemia models.
• Diabetic Complications Research: Studies have examined ARA-290’s effects on metabolic control, corneal nerve density, and peripheral neuropathy in diabetic models.
• Sarcoidosis and Neuropathic Pain: Clinical research has investigated ARA-290 for small-fiber neuropathy and neuropathic pain in sarcoidosis patients.

Evidently, researchers can buy ARA-290 16mg in Switzerland for these applications, as it is a valuable addition to any laboratory toolkit focused on tissue protection, neuroinflammation, and regenerative signaling research.

ARA-290 Product Specifications

Specification	Details
Product Name	ARA-290 (Cibinetide)
Alternative Names	Cibinetide, PHBSP, Pyroglutamate HBSP, Pyroglutamate Helix B Surface Peptide
Amount	16mg
Form	Lyophilized powder
Purity	Not verified
Amino Acid Sequence	Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (Pyr-EQLERALNSS)
Sequence Full	Pyroglutamyl-glutamyl-glutaminyl-leucyl-glutamyl-arginyl-alanyl-leucyl-asparaginyl-seryl-serine
Length	11 amino acids
Molecular Formula	C₅₁H₈₄N₁₆O₂₁
Molecular Weight	1,257.3 g/mol (free base)
CAS Number	1208243-50-8
PubChem CID	91810664
Research Category	Immunity & Inflammation / Healing & Regeneration
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below

How to Evaluate ARA-290 Quality for Research

When sourcing ARA-290 peptide for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the compound’s molecular weight (1,257.3 g/mol) and sequence (Pyr-EQLERALNSS).
• Purity Assessment: High-performance liquid chromatography (HPLC) can provide information about peptide purity.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount, sequence, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptides and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptide they are using in their laboratory investigations.

Storage and Stability of ARA-290

Core Peptides supplies ARA-290 as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents
• Gently swirl to dissolve; do not vortex
• Filter sterilize if required (e.g., 0.22 µm) immediately prior to use
• If stock solutions are required, store as aliquots in tightly sealed vials at -20°C
• Protect from light and moisture

Frequently Asked Questions About Buying ARA-290 16mg in Switzerland

What is ARA-290?

Specifically, ARA-290 (Cibinetide) is a synthetic 11-amino acid linear peptide derived from the helix-B domain of erythropoietin (EPO) with the sequence Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser.

What is ARA-290 researched for?

Primarily, researchers study ARA-290 for its role as a selective agonist of the innate repair receptor (IRR). Studies have investigated its effects on tissue protection, neuroprotection, anti-inflammatory signaling, and nerve regeneration.

How does ARA-290 work?

Mechanistically, ARA-290 functions by selectively binding to and activating the innate repair receptor (IRR), a heterodimer of EPOR and CD131. This activation triggers anti-inflammatory signaling, JAK2-STAT pathways, and tissue-protective responses without stimulating red blood cell production.

What is the amino acid sequence of ARA-290?

The amino acid sequence is Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (Pyr-EQLERALNSS), where Pyr represents pyroglutamic acid.

What is the molecular weight of ARA-290?

The molecular weight is approximately 1,257.3 g/mol (free base).

What is the molecular formula of ARA-290?

The molecular formula is C₅₁H₈₄N₁₆O₂₁.

What is the CAS number of ARA-290?

The CAS number is 1208243-50-8.

Is ARA-290 synthetic?

Yes, ARA-290 is a synthetic peptide produced through solid-phase peptide synthesis.

Is ARA-290 erythropoietic?

No. ARA-290 is a non-erythropoietic peptide that does not stimulate red blood cell production. It selectively activates the innate repair receptor without engaging the classical EPOR homodimer.

What research exists on ARA-290?

Research on ARA-290 includes preclinical studies in rodent models of sciatic nerve injury, diabetic vasculopathy, and aging, as well as clinical trials in sarcoidosis-associated small-fiber neuropathy and diabetic peripheral neuropathy. ARA-290 has received Orphan Drug and Fast Track designations from the U.S. FDA.

Is ARA-290 approved as a medicine?

No. Regulatory authorities have not approved ARA-290 as a medicine, pharmaceutical, or therapeutic agent. It remains in clinical development as of 2026.

Is ARA-290 intended for human use?

No. ARA-290 is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy ARA-290 16mg in Switzerland?

You can buy ARA-290 16mg in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate ARA-290 quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in ARA-290 may also find the following related compounds relevant to their work:

• Full-Length Erythropoietin (EPO) — The parent molecule from which ARA-290 is derived, researched for erythropoiesis and tissue protection.
• BPC-157 — A peptide researched for tissue healing, gastrointestinal health, and angiogenesis.
• TB-500 — A Thymosin Beta 4 fragment researched for tissue repair and wound healing.
• GHK-Cu — A copper-binding peptide researched for skin regeneration, wound healing, and anti-aging applications.

Explore Immunity & Inflammation

ARA-290 belongs to the Immunity & Inflammation category of research compounds. Immunity & Inflammation products are studied for their potential roles in inflammatory signaling, immune modulation, and tissue protection. Generally, researchers who buy ARA-290 16mg in Switzerland often pair it with related compounds in this category to explore complementary pathways in inflammation research and tissue-protective signaling.

Explore Healing & Regeneration

Researchers studying tissue repair, neuroprotection, and regenerative mechanisms may also find relevant compounds in the Healing & Regeneration category. ARA-290’s tissue-protective and neuroregenerative properties make it a valuable tool for investigating peripheral nerve regeneration, ischemic injury, and chronic inflammation.

Further Research

For researchers seeking to deepen their understanding of ARA-290 and its research applications, the following areas may warrant further investigation:

• The relationship between ARA-290-mediated IRR activation and specific downstream signaling pathways in different cell types
• Comparative studies between ARA-290 and full-length EPO in various tissue protection and inflammation models
• The potential role of ARA-290 in modulating NLRP3 inflammasome activation and neuroinflammation
• Mechanistic studies on ARA-290’s interaction with the EPOR/CD131 heterodimer and other receptor complexes
• Exploration of ARA-290’s effects on different tissue systems beyond neural and vascular biology

Research Disclaimer

ARA-290 is a research peptide supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptides should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.